while our patient had low IgG (1.76 g/L) and IgA (0.28 g/L). We could speculate that humoral dysfunction related to rituximab therapy could have caused loss neutralization of free viral particles by specific antibodies, facilitating initial dissemination of the VZV but this hypothesis needs to be investigated further.

Arancha Bermúdez, Fernando Marco, Eulogio Conde, Enrique Mazo, Marina Recio, Alberto Zubizarreta
Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Key words
Rituximab, visceral varicella-zoster infection, lymphoma.

Correspondence
Arancha Bermúdez, Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n. 39008 Santander, Spain. Phone: international +34-942-202573 – Fax: international +34-942-203450.

References

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies

Sir,

A 56-year old man with chronic obstructive pulmonary disease was admitted because of hemoptysis. There was no evidence of malignancy, tuberculosis or autoimmune disorders. The patient did not take any new drug before admission. Routine coagulation tests showed repeatedly a prolongation of the activated partial thromboplastin time (to 63.7 sec, upper normal value 37 sec). This was due to a decrease of factor VIII:C to 0.04 IU/mL with an antibody level against factor VIII of 40 Bethesda units/mL. An acquired von Willebrand syndrome was excluded (vWF:Ag of 2.38 IU/mL, vWF:Rco of 1 IU/mL). Treatment during 3 months with prednisone (initially 1 mg/kg/day) and cyclophosphamide 50 mg p.o. daily, followed by i.v. gammaglobulins (0.4 g/kg/day for 5 days) had no influence on the presence of the antibodies. Later on a subcutaneous hemorrhage in the left arm and bleeding in the sural muscles of the right leg occurred. During that period recombinant activated factor VII was successfully administered. After initiation of cyclosporin, the antibodies against factor VIII progressively decreased and finally disappeared. The treatment was stopped after eight months. The coagulation tests remained normal. Spontaneously acquired antibodies against factor VIII are infrequent. They peak in the third and seventh decades.1 Intramuscular bleeds are the most common hemorrhagic manifestation. The major cause of acquired antibodies against factor VIII, excluding hemophilia, are autoimmune disorders,
malignant diseases, pregnancy or drug reactions. In about 50% of the cases no underlying disease can be identified. The prognosis is poor if untreated. Spontaneous disappearance of the inhibitor has been reported, but after a long delay. Acute bleeding periods can be treated with recombinant activated factor VII, as in hemophiliacs with inhibitors. Alternatives include large doses of factor VIII, a porcine factor VIII, prothrombin complex concentrates (PCC) and activated PCC. The most frequently used treatments for elimination of the antibodies include oral corticosteroids and cyclophosphamide. A high dose of i.v. gammaglobulins can also be effective. The alternatives are interferon, a combination of steroids, cyclophosphamide and vincristine, or combination chemotherapy. The effect of replacement therapy or removing antibodies by plasmapheresis is only transient. The experience with cyclosporine shows that it might be effective in the treatment of acquired hemophilia with a high antibody titer against factor VIII. Cyclosporine inhibits cell-mediated reactions and plays a role in the induction of immune tolerance against factor VIII. It does not affect hematopoiesis and causes fewer infectious complications. This drug could be considered as a possible treatment of acquired hemophilia if other modalities fail.

Mirko Petrovic, Eric Derom, Gaston Baele
Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

Key words
Cyclosporine, acquired hemophilia.

Correspondence
Mirko Petrovic, M.D, Department of Internal Medicine, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium. Phone: international +32-9-2402168 – Fax: international +32-9-2403053 – E-mail: mirko.petrovic@rug.ac.be

References